remdesivir - versus standard of care - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.86 [0.37, 2.01]< 10%3 studies (3/-)63.5 %some concernnot evaluable moderatecrucial-
deaths 0.95 [0.81, 1.11]< 10%4 studies (4/-)75.6 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.94 [0.81, 1.10]< 10%3 studies (3/-)77.0 %some concernnot evaluable moderatecrucial-
clinical improvement 1.38 [0.98, 1.95]> 130%2 studies (2/-)96.6 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.57 [1.15, 2.16]> 10%2 studies (2/-)99.8 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.81 [1.19, 2.76]> 10%2 studies (2/-)99.7 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.20 [0.88, 1.63]> 117%2 studies (2/-)87.8 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.15 [0.99, 1.34]> 10%2 studies (2/-)96.9 %some concernnot evaluable moderateimportant-
death or ventilation 0.97 [0.85, 1.10]< 10%1 study (1/-)67.8 %NAnot evaluable important-
mechanical ventilation 0.87 [0.39, 1.96]< 129%4 studies (4/-)63.1 %some concernnot evaluable moderateimportant-
recovery 1.15 [0.99, 1.33]> 10%2 studies (2/-)96.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.53 [0.30, 0.94]< 10%2 studies (2/-)98.6 %some concernnot evaluable moderateimportant-
adverse events 1.40 [1.05, 1.87]< 14%2 studies (2/-)1.0 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.